Viridian Therapeutics, Inc. revenue breakdown overview

Viridian Therapeutics, Inc. revenue for the last year amounted to 314.00 k USD, the most of which — 314.00 k USD — came from its highest performing source at the moment, Monoclonal Antibody, the year earlier bringing 1.77 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Viridian Therapeutics, Inc. 314.00 k USD, and the year before that — 1.77 M USD.